Your browser doesn't support javascript.
loading
Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.
Zou, Xinhua; Fan, Wenzhe; Xue, Miao; Li, Jiaping.
Affiliation
  • Zou X; Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, Guangdong Province, 510080, People's Republic of China.
  • Fan W; Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, Guangdong Province, 510080, People's Republic of China.
  • Xue M; Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, Guangdong Province, 510080, People's Republic of China.
  • Li J; Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, Guangdong Province, 510080, People's Republic of China.
Cancer Manag Res ; 13: 4013-4029, 2021.
Article de En | MEDLINE | ID: mdl-34040442
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cancer Manag Res Année: 2021 Type de document: Article Pays de publication: Nouvelle-Zélande
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cancer Manag Res Année: 2021 Type de document: Article Pays de publication: Nouvelle-Zélande